| Date Filed | Type | Description |
| 08/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/11/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/11/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 06/09/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/09/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/08/2023 |
SC TO-I/A
| Form SC TO-I/A - Tender offer statement by Issuer: [Amend] |
| 06/08/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Submission of Matters to a ...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amendment No. 1 to Warrant Agreement, by and between the Company and Continental Stock Transfer & Trust Company",
"Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX - June 8, 2023 - Biote , a leading solutions provider in preventive healthcare through the delivery of personalized hormone therapy, today announced the expiration and results of its previously announced offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share , of the Company, at an exercise price of $11.50 per share , the opportunity to receive 0.23 shares of Common Stock in exchange for each Warrant tendered by the holder and exchanged pursuant to the offer , and solicitation of consents from holders of the Warrants to amend the Warrant Agreement, dated as of March 1, 2021 , by and bet..." |
|
| 06/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement, by and among the Company, Roth Capital Partners, LLC, as the underwriter, and the Selling Stockholder named therein",
"Underwriting Agreement, by and among the Company, Roth Capital Partners, LLC, as the underwriter, and the Selling Stockholder named therein" |
|
| 06/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/23/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 05/19/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/16/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 05/16/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/16/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/10/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/09/2023 |
SC TO-I
| Form SC TO-I - Tender offer statement by Issuer: |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biote Reports First Quarter 2023 Financial Results New Initiative Targets Long-term Growth Opportunity in Men's Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance",
"Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX - May 9, 2023 - Biote , a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer and consent solicitation relating to its 8,397,624 outstanding public warrants to purchase Class A common stock of the Company $0.0001 par value per share , which warrants trade on the Nasdaq Stock Market under the symbol “BTMDW” and 5,106,508 private placement warrants . The purpose of the Offer and Consent Solicitation is to simplify the Company's capital structure and reduce the potential dilutive impact of the warrants. Until the Expiration Date , we are offering to the holders of Warrants the oppo..." |
|
| 05/09/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 04/24/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 04/14/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/05/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 04/05/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/29/2023 |
10-Q/A
| Quarterly Report for the period ended September 30, 2022 [amend] |
|